BC Extra | Sep 10, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

Sanofi to pay Lexicon $260M as Zynquista ends  Sanofi (NASDAQ:SNY) will pay Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) $208 million up front plus $52 million over the next 12 months as part of the companies’ agreement to...
BC Extra | Aug 12, 2019
Company News

Management tracks: Bailey leaving GSK; plus HHS drug pricing adviser to depart and more

Jack Bailey will step down as president of U.S. Pharmaceuticals at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) at year end. He will be replaced by Maya Martinez-Davis, who is regional president for Latin America at the EMD...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Extra | Dec 20, 2018
Company News

Management tracks: Evox names Moses chairman; Kapeller joins GV

Exosome therapy company Evox Therapeutics Ltd. (Oxford, U.K.) appointed Edwin Moses as chairman. This month, the former Ablynx N.V. CEO was also appointed chairman of Virion Biotherapeutics Ltd. (London, U.K.) and Achilles Therapeutics Ltd. (Stevenage,...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Stepping Through

Once considered obstacles to biomedical product development, regulators around the world have become enablers of the kinds of scientific and economic innovations that will underpin new business models. They are building gateways that could help...
BC Week In Review | Jul 20, 2018
Company News

Tasly gets Chinese rights to two cell therapies from Mesoblast

Tasly Pharmaceutical Co. Ltd. (Shanghai:600535) received exclusive, Chinese rights to develop and commercialize mesenchymal precursor cell candidates MPC-150-IM and MPC-25-IC from Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO). Mesoblast will receive a $40 million upfront payment comprising a...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BC Extra | May 31, 2018
Company News

Management tracks: Axcella, Arcturus, Orexo

Metabolic dysregulation company Axcella Health Inc. (Cambridge, Mass.) hired William Hinshaw as president and CEO. He was EVP and head of U.S. oncology at Novartis AG (NYSE:NVS; SIX:NOVN). RNA therapeutics company Arcturus Therapeutics Ltd. (NASDAQ:ARCT)...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
Items per page:
1 - 10 of 132
BC Extra | Sep 10, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

Sanofi to pay Lexicon $260M as Zynquista ends  Sanofi (NASDAQ:SNY) will pay Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) $208 million up front plus $52 million over the next 12 months as part of the companies’ agreement to...
BC Extra | Aug 12, 2019
Company News

Management tracks: Bailey leaving GSK; plus HHS drug pricing adviser to depart and more

Jack Bailey will step down as president of U.S. Pharmaceuticals at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) at year end. He will be replaced by Maya Martinez-Davis, who is regional president for Latin America at the EMD...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Extra | Dec 20, 2018
Company News

Management tracks: Evox names Moses chairman; Kapeller joins GV

Exosome therapy company Evox Therapeutics Ltd. (Oxford, U.K.) appointed Edwin Moses as chairman. This month, the former Ablynx N.V. CEO was also appointed chairman of Virion Biotherapeutics Ltd. (London, U.K.) and Achilles Therapeutics Ltd. (Stevenage,...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Stepping Through

Once considered obstacles to biomedical product development, regulators around the world have become enablers of the kinds of scientific and economic innovations that will underpin new business models. They are building gateways that could help...
BC Week In Review | Jul 20, 2018
Company News

Tasly gets Chinese rights to two cell therapies from Mesoblast

Tasly Pharmaceutical Co. Ltd. (Shanghai:600535) received exclusive, Chinese rights to develop and commercialize mesenchymal precursor cell candidates MPC-150-IM and MPC-25-IC from Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO). Mesoblast will receive a $40 million upfront payment comprising a...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BC Extra | May 31, 2018
Company News

Management tracks: Axcella, Arcturus, Orexo

Metabolic dysregulation company Axcella Health Inc. (Cambridge, Mass.) hired William Hinshaw as president and CEO. He was EVP and head of U.S. oncology at Novartis AG (NYSE:NVS; SIX:NOVN). RNA therapeutics company Arcturus Therapeutics Ltd. (NASDAQ:ARCT)...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
Items per page:
1 - 10 of 132